Advertisement
CTMX vs MLEC
Which Stock Would AI Choose? CytomX Therapeutics (CTMX) vs. Moolec Science (MLEC) Stock Comparison
Key Takeaways
- CytomX Therapeutics (CTMX) is a clinical-stage oncology biotech with a strengthened cash position and a lead antibody-drug conjugate (ADC) candidate, but its share price has weakened in recent weeks.
- Moolec Science (MLEC) is a molecular-farming food-ingredient company that has faced major corporate restructuring, listing-compliance issues, and a steep decline in market value.
- The two stocks sit at opposite ends of the risk spectrum: CTMX is a mid-cap biotech (~$496 million market cap), while MLEC is a micro-cap (~$3 million) navigating structural uncertainty.
- Analyst consensus on CTMX remains favorable despite price weakness; MLEC has limited sell-side coverage and significant going-concern and governance considerations.
- Relative performance diverges sharply, with CTMX showing more stable, trend-consistent trading than MLEC's high-volatility, event-driven moves.
- For more detail, explore CTMX Major News and CTMX Today's Price Move, as well as MLEC Major News and MLEC Today's Price Move.
- Discover how AI evaluates setups like these by visiting Trending AI Robots.
Introduction
Investors and traders evaluating speculative growth stories often weigh a high-conviction clinical-stage biotech against a small-cap "frontier technology" name. CTMX (CytomX Therapeutics) and MLEC (Moolec Science) offer a useful contrast in market positioning, capital structure, and risk. This stock comparison examines how each company has performed during recent market activity, what has driven sentiment, and how their relative performance and growth drivers differ. The comparison is most relevant to traders seeking volatility signals and to long-term investors assessing whether innovation-focused micro- and mid-caps warrant allocation within a diversified portfolio.
CTMX Overview and Recent Performance
CytomX Therapeutics is a South San Francisco-based clinical-stage biopharmaceutical company focused on oncology. Its core platform, Probody, uses antibody-masking technology to develop conditionally activated therapeutics, including ADCs (antibody-drug conjugates, which deliver a toxic drug payload directly to cancer cells). The lead program, Varseta-M, targets EpCAM in late-line colorectal cancer and has reported encouraging early efficacy signals, including a confirmed overall response rate in the 20–32% range.
Financially, the company materially strengthened its balance sheet in recent quarters, reporting roughly $346.7 million in cash and investments as of the end of the first quarter of 2026, extending its runway into late 2028. However, revenue has declined sharply year over year as legacy collaborations wind down. Despite a favorable analyst consensus (a "Strong Buy" with an average price target near $12), the stock has traded down over recent weeks and months, reflecting broader biotech-sector pressure, elevated short interest, and the inherent risk of awaiting pivotal clinical and regulatory milestones.
MLEC Overview and Recent Performance
Moolec Science is a science-based food-ingredient company that uses molecular farming and precision fermentation to produce animal proteins and specialty oils in plants such as safflower, soy, and peas. Its technology platform aims to combine the functionality of animal-derived ingredients with plant-based production economics.
MLEC's recent market activity has been dominated by corporate and structural events rather than steady operational progress. The company underwent a change of control, with Agriculture Investment Group Corp. becoming its controlling shareholder, and it worked through Nasdaq Capital Market continued-listing requirements. Reported developments also indicate shareholders approved a voluntary liquidation, and the stock has declined from much higher levels over the past year, leaving a market capitalization of only a few million dollars. With thin trading volume, limited analyst coverage, and negative equity, MLEC currently exhibits micro-cap characteristics with substantial liquidity and governance risks.
Trending AI Robots
Tickeron maintains a large library of AI trading bots that monitor thousands of different tickers across varying timeframes and strategies. Because market conditions change constantly, only a select subset of these bots earns a place in the curated Trending AI Robots section. The bots featured there differ in trading style, strategy, timeframe, performance statistics, and the specific tickers they follow, allowing users to review a focused selection of systems currently aligned with prevailing market behavior. Exploring this section can help traders see how systematic, signal-driven approaches assess setups such as those presented by CTMX and MLEC.
Head-to-Head Comparison
The most striking difference is scale and capital structure. CTMX carries a market capitalization roughly 150 times larger than MLEC and holds a multi-year cash runway, while MLEC operates with a minimal market value, negative equity, and a shrinking public float. In terms of business model, CTMX is a pure-play oncology developer with a single lead clinical asset and a near-term catalyst path; MLEC is a diversified agri-food ingredient platform whose near-term narrative is driven by restructuring, deconsolidation, and listing compliance.
On growth drivers, CTMX's value hinges on clinical data and potential regulatory advancement, whereas MLEC's path depends on operational commercialization and capital restructuring. Risk factors also diverge: CTMX faces binary clinical risk and heavy short interest, while MLEC faces liquidity, going-concern, and governance risk. Sector exposure differs as well—CTMX sits in biotech/oncology, and MLEC spans food technology and agriculture. Recent momentum has been negative for both, but CTMX's moves have been more trend-consistent, whereas MLEC has shown sharp, event-driven swings with limited institutional support.
Tickeron AI Verdict
Based on observable factors such as trend consistency, balance-sheet stability, institutional coverage, and catalyst visibility, Tickeron's AI would likely favor CTMX over MLEC in the current environment. CTMX exhibits a more stable trading profile, a materially stronger cash position, and a clearer—though still binary—catalyst pathway, while MLEC's micro-cap structure and structural uncertainty introduce higher, less quantifiable risk. This relative positioning is probabilistic rather than definitive, and either name could experience sharp moves tied to company-specific news.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CTMX is a Hold and MLEC is a Buy.
CTMX in +6.07% Uptrend, advancing for three consecutive days on October 28, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CTMX advanced for three days, in 182 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CTMX's RSI Indicator exited the oversold zone, 33 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
CTMX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CTMX as a result. In 76 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for CTMX turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 36 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTMX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CTMX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.580) is normal, around the industry mean (3.498). P/E Ratio (-3.842) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (27.624) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. CTMX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MLEC's RSI Oscillator stays in oversold zone for 22 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MLEC just turned positive on October 27, 2026. Looking at past instances where MLEC's MACD turned positive, the stock continued to rise in 40 of 59 cases over the following month. The odds of a continued upward trend are 68%.
Following a +3.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLEC advanced for three days, in 102 of 145 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
MLEC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MLEC entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.221) is normal, around the industry mean (3.498). P/E Ratio (-0.003) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.011) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. MLEC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CTMX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 85 | |
P/E GROWTH RATING 1..100 | 98 | |
SEASONALITY SCORE 1..100 | 10 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CTMX | MLEC | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 75% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 74% | N/A |
| Momentum ODDS (%) | 2 days ago 87% | N/A |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 68% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 53% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| Advances ODDS (%) | 15 days ago 77% | 20 days ago 70% |
| Declines ODDS (%) | 9 days ago 88% | 16 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 69% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CTMX’s FA Score shows that 1 FA rating(s) are green while MLEC’s FA Score has 1 green FA rating(s).
- CTMX’s FA Score: 1 green, 4 red.
- MLEC’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CTMX’s TA Score shows that 4 TA indicator(s) are bullish while MLEC’s TA Score has 4 bullish TA indicator(s).
- CTMX’s TA Score: 4 bullish, 4 bearish.
- MLEC’s TA Score: 4 bullish, 2 bearish.
Price Growth
CTMX (@Biotechnology) experienced а -9.17% price change this week, while MLEC (@Biotechnology) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
CTMX is expected to report earnings on Feb 24, 2027.
MLEC is expected to report earnings on Dec 17, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CTMX and
Correlation & Price change
A.I.dvisor indicates that over the last year, CTMX has been loosely correlated with MLEC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CTMX jumps, then MLEC could also see price increases.
| Ticker / NAME | Correlation To CTMX | 1D Price Change % | ||
|---|---|---|---|---|
| CTMX | 100% | N/A | ||
| MLEC - CTMX | 42% Loosely correlated | N/A | ||
| VKTX - CTMX | 41% Loosely correlated | -1.14% | ||
| IMTX - CTMX | 40% Loosely correlated | -0.16% | ||
| EDIT - CTMX | 40% Loosely correlated | -8.91% | ||
| AURA - CTMX | 38% Loosely correlated | -0.13% | ||
More | ||||